Comment
doi: 10.1038/s41571-020-00451-3.
Chemotherapy: not for Ph+-ALL
Affiliations
- PMID: 33169006
- DOI: 10.1038/s41571-020-00451-3
Item in Clipboard
Comment
Chemotherapy: not for Ph+-ALL
Nat Rev Clin Oncol.
2021 Jan.
No abstract available
Comment on
-
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
Similar articles
-
Dasatinib-Blinatumomab for Ph-Positive ALL. Reply.N Engl J Med. 2021 Jan 28;384(4):384. doi: 10.1056/NEJMc2033785. N Engl J Med. 2021. PMID: 33503352 No abstract available.
-
Chemotherapy-free Treatment - A New Era in Acute Lymphoblastic Leukemia?N Engl J Med. 2020 Oct 22;383(17):1673-1674. doi: 10.1056/NEJMe2027937. N Engl J Med. 2020. PMID: 33085866 No abstract available.
-
Dasatinib-Blinatumomab for Ph-Positive ALL.N Engl J Med. 2021 Jan 28;384(4):384. doi: 10.1056/NEJMc2033785. N Engl J Med. 2021. PMID: 33503351 No abstract available.
-
Blinatumomab (Blincyto) for acute lymphoblastic leukemia.Med Lett Drugs Ther. 2015 May 11;57(1468):e74-5. Med Lett Drugs Ther. 2015. PMID: 25941958 Review.
-
Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.Expert Opin Investig Drugs. 2019 May;28(5):411-420. doi: 10.1080/13543784.2019.1597052. Epub 2019 Apr 5. Expert Opin Investig Drugs. 2019. PMID: 30916583 Review.
References
Original article
-
- Foà, R. et al. Dasatinib–blinatumomab for Ph-positive acute lymphoblastic leukaemia in adults. N. Engl. J. Med. 383, 1613–1623 (2020) - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
